請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65551
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 簡國龍(Kuo-Liong Chien) | |
dc.contributor.author | Jing-Ling Luo | en |
dc.contributor.author | 羅景齡 | zh_TW |
dc.date.accessioned | 2021-06-16T23:49:58Z | - |
dc.date.available | 2012-09-17 | |
dc.date.copyright | 2012-09-17 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-20 | |
dc.identifier.citation | 1. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: Findings From the Resource Utilization Among Congestive Heart Failure (reach) Study. Journal of the American College of Cardiology. 2002;39:60-69
2. Al-Mohammad A, Mant J. The diagnosis and management of chronic heart failure: Review following the publication of the nice guidelines. Heart. 2011;97:411-416 3. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham study. Journal of the American College of Cardiology. 1993;22:6A-13A 4. Kupari M, Lindroos M, Iivanainen AM, Heikkila J, Tilvis R. Congestive heart failure in old age: Prevalence, mechanisms and 4-year prognosis in the Helsinki ageing study. Journal of Internal Medicine. 1997;241:387-394 5. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, Oliveira A. Prevalence of chronic heart failure in southwestern europe: The epica study. European Journal of Heart Failure. 2002;4:531-539 6. Huang CH, Chien KL, Chen WJ, Sung FC, Hsu HC, Su TC, Lee YT. Impact of heart failure and left ventricular function on long-term survival--report of a community-based cohort study in Taiwan. European Journal of Heart Failure. 2007;9:587-593 7. Mehta PA, Dubrey SW, McIntyre HF, Walker DM, Hardman SM, Sutton GC, McDonagh TA, Cowie MR. Improving survival in the 6 months after diagnosis of heart failure in the past decade: Population-based data from the UK. Heart. 2009;95:1851-1856 8. The nhs information centre for health and social care. (2010) national heart failure audit 2010 (report for the audit period between april 2009 and march 2010). Http://www.Ic.Nhs.Uk/webfiles/publications/002_audits/heart_failure_audit_2010_v1.0_08-12-10.Pdf. . 9. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted county, Minnesota. Circulation. 2007;115:1982-1990 10. How to diagnose diastolic heart failure. European study group on diastolic heart failure. European Heart Journal. 1998;19:990-1003 11. Galderisi M. Diastolic dysfunction and diastolic heart failure: Diagnostic, prognostic and therapeutic aspects. Cardiovascular Ultrasound. 2005;3:9 12. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal. 2008;29:2388-2442 13. Paulus WJ. Novel strategies in diastolic heart failure. Heart. 2010;96:1147-1153 14. van den Hurk K, Alssema M, Kamp O, Henry RM, Stehouwer CD, Smulders YM, Nijpels G, Paulus WJ, Dekker JM. Independent associations of glucose status and arterial stiffness with left ventricular diastolic dysfunction: An 8-year follow-up of the hoorn study. Diabetes Care. 2012 15. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1975;22:215-227 16. Nakhai-Pour HR, Grobbee DE, Bots ML, Muller M, van der Schouw YT. Circulating homocysteine and large arterial stiffness and thickness in a population-based sample of middle-aged and elderly men. Journal of Human Hypertension. 2007;21:942-948 17. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. American Journal of Human Genetics. 1985;37:1-31 18. Clarke R, Halsey J, Bennett D, Lewington S. Homocysteine and vascular disease: Review of published results of the homocysteine-lowering trials. Journal of Inherited Metabolic Disease. 2011;34:83-91 19. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, Walter JH, Howard PM, Naughten ER. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: A multicenter observational study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:2080-2085 20. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. The Journal of Clinical Investigation. 1976;57:1079-1082 21. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: An independent risk factor for vascular disease. The New England Journal of Medicine. 1991;324:1149-1155 22. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057 23. Sun Y, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT. Use of serum homocysteine to predict stroke, coronary heart disease and death in ethnic chinese. 12-year prospective cohort study. Circulation Journal 2009;73:1423-1430 24. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: Systematic review of published epidemiological studies. Journal of Cardiovascular Risk. 1998;5:229-232 25. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002;288:2015-2022 26. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. The New England Journal of Medicine. 2001;345:1593-1600 27. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin 12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: The Swiss heart study: A randomized controlled trial. JAMA 2002;288:973-979 28. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. The New England Journal of Medicine. 2004;350:2673-2681 29. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C, Stampfer MJ. Folate and vitamin b6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359-364 30. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J, Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. The New England Journal of Medicine. 2006;354:1567-1577 31. Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, Collins R. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: A randomized trial. JAMA 2010;303:2486-2494 32. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le Cessie S, Gussekloo J. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: Population based observational cohort study. BMJ. 2009;338:a3083 33. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA 2006;296:2720-2726 34. Loscalzo J. Homocysteine trials--clear outcomes for complex reasons. The New England Journal of Medicine. 2006;354:1629-1632 35. Shantsila E, Lip GY, Gill PS. Systolic heart failure in south asians. International Journal of Clinical Practice. 2011;65:1274-1282 36. McCully KS. Chemical pathology of homocysteine. Iv. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Annals of Clinical and Laboratory Science. 2009;39:219-232 37. Steed MM, Tyagi SC. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxidants & Redox Signaling. 2011;15:1927-1943 38. Fowler B. Homocysteine: Overview of biochemistry, molecular biology, and role in disease processes. Seminars in Vascular Medicine. 2005;5:77-86 39. Moshal KS, Metreveli N, Frank I, Tyagi SC. Mitochondrial mmp activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Current Vascular Pharmacology. 2008;6:84-92 40. Blacher J, Demuth K, Guerin AP, Vadez C, Moatti N, Safar ME, London GM. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. Journal of Nephrology. 1999;12:248-255 41. Joseph J, Washington A, Joseph L, Koehler L, Fink LM, Hauer-Jensen M, Kennedy RH. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. American Journal of Physiology. Heart and Circulatory Physiology. 2002;283:H2567-2574 42. Joseph J, Joseph L, Shekhawat NS, Devi S, Wang J, Melchert RB, Hauer-Jensen M, Kennedy RH. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. American Journal of Physiology. Heart and Circulatory Physiology. 2003;285:H679-686 43. Walker E, Black J, Parris C, Bryda EC, Cansino S, Hunt L, Chappell J, Wehner P, Studeny M, Wright GL. Effect of experimental hyperhomocysteinemia on cardiac structure and function in the rat. Annals of Clinical and Laboratory Science. 2004;34:175-180 44. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, Rosenberg IH, Wilson PW. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003;289:1251-1257 45. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, Thomson A, Ueland PM, Ebrahim SB. Serum total homocysteine and coronary heart disease: Prospective study in middle aged men. Heart. 1999;82:448-454 46. Chao CL, Tsai HH, Lee CM, Hsu SM, Kao JT, Chien KL, Sung FC, Lee YT. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis. 1999;147:379-386 47. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. The New England Journal of Medicine. 1998;338:1042-1050 48. Lentz SR. Homocysteine and vascular dysfunction. Life Sciences. 1997;61:1205-1215 49. Chilian WM. Coronary microcirculation in health and disease. Summary of an nhlbi workshop. Circulation. 1997;95:522-528 50. Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC. Hyperhomocysteinemia evoked by folate depletion: Effects on coronary and carotid arterial function. Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:772-780 51. Al-Obaidi MK, Stubbs PJ, Collinson P, Conroy R, Graham I, Noble MI. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. Journal of the American College of Cardiology. 2000;36:1217-1222 52. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. The Journal of Clinical Investigation. 1996;98:5-7 53. Herrmann M, Kindermann I, Muller S, Georg T, Kindermann M, Bohm M, Herrmann W. Relationship of plasma homocysteine with the severity of chronic heart failure. Clinical chemistry. 2005;51:1512-1515 54. Naruszewicz M, Jankowska EA, Zymlinski R, Bukowska H, Millo B, Banasiak W, Ponikowski P. Hyperhomocysteinemia in patients with symptomatic chronic heart failure: Prevalence and prognostic importance--pilot study. Atherosclerosis. 2007;194:408-414 55. Kennedy RH, Owings R, Shekhawat N, Joseph J. Acute negative inotropic effects of homocysteine are mediated via the endothelium. American Journal of Physiology. Heart and Circulatory Physiology. 2004;287:H812-817 56. Naono S, Tamura A, Kadota J. Plasma homocysteine level is unrelated to long-term cardiovascular events in patients with previous percutaneous coronary intervention. Journal of Cardiology. 2009;54:21-28 57. Nasir K, Tsai M, Rosen BD, Fernandes V, Bluemke DA, Folsom AR, Lima JA. Elevated homocysteine is associated with reduced regional left ventricular function: The multi-ethnic study of atherosclerosis. Circulation. 2007;115:180-187 58. May HT, Alharethi R, Anderson JL, Muhlestein JB, Reyna SP, Bair TL, Horne BD, Kfoury AG, Carlquist JF, Renlund DG. Homocysteine levels are associated with increased risk of congestive heart failure in patients with and without coronary artery disease. Cardiology. 2007;107:178-184 59. Alter P, Rupp H, Rominger MB, Figiel JH, Renz H, Klose KJ, Maisch B. Association of hyperhomocysteinemia with left ventricular dilatation and mass in human heart. Clinical Chemistry and Laboratory Medicine 2010;48:555-560 60. Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, Rosenberg IH, Levy D, Wilson PW, Vasan RS. Relations of plasma homocysteine to left ventricular structure and function: The Framingham heart study. European Heart Journal. 2004;25:523-530 61. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. American Journal of Epidemiology. 2002;156:1105-1113 62. Gueant-Rodriguez RM, Juilliere Y, Nippert M, Abdelmouttaleb I, Herbeth B, Aliot E, Danchin N, Gueant JL. Left ventricular systolic dysfunction is an independent predictor of homocysteine in angiographically documented patients with or without coronary artery lesions. Journal of Thrombosis and Haemostasis 2007;5:1209-1216 63. Vizzardi E, Nodari S, Fiorina C, Metra M, Dei Cas L. Raised homocysteine plasma concentration in patients with heart failure: Clinical significance. Monaldi Archives for Chest Disease 2007;68:96-102 64. Okuyan E, Uslu A, Cakar MA, Sahin I, Onur I, Enhos A, Biter HI, Cetin S, Dinckal MH. Homocysteine levels in patients with heart failure with preserved ejection fraction. Cardiology. 2010;117:21-27 65. Agoston-Coldea L, Mocan T, Gatfosse M, Lupu S, Dumitrascu DL. Plasma homocysteine and the severity of heart failure in patients with previous myocardial infarction. Cardiology Journal. 2011;18:55-62 66. Lee Y, Lin RS, Sung FC, Yang C, Chien K, Chen W, Su T, Hsu H, Huang Y. Chin-shan community cardiovascular cohort in Taiwan-baseline data and five-year follow-up morbidity and mortality. Journal of Clinical Epidemiology. 2000;53:838-846 67. Dumesnil JG, Shoucri RM. Effect of the geometry of the left ventricle on the calculation of ejection fraction. Circulation. 1982;65:91-98 68. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613-618 69. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. The American Journal of Physiology. 1984;247:F632-636 70. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. Journal of the American College of Cardiology. 1992;20:1251-1260 71. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. European Journal of Echocardiography 2009;10:165-193 72. de Marchi SF, Windecker S, Aeschbacher BC, Seiler C. Influence of left ventricular relaxation on the pressure half time of aortic regurgitation. Heart. 1999;82:607-613 73. Indermuhle A, Vogel R, Meier P, Wirth S, Stoop R, Mohaupt MG, Seiler C. The relative myocardial blood volume differentiates between hypertensive heart disease and athlete's heart in humans. European Heart Journal. 2006;27:1571-1578 74. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst(e)ine with the abbott imx analyzer. Clinical Chemistry. 1995;41:991-994 75. Chao CL, Kuo TL, Lee YT. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation. 2000;101:485-490 76. Refsum H, Ueland PM, Svardal AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clinical Chemistry. 1989;35:1921-1927 77. Palta M, Lin CY. Latent variables, measurement error and methods for analysing longitudinal binary and ordinal data. Statistics in Medicine. 1999;18:385-396 78. Korn EL, Simon R. Measures of explained variation for survival data. Statistics in Medicine. 1990;9:487-503 79. Wiegand RE. Performance of using multiple stepwise algorithms for variable selection. Statistics in Medicine. 2010;29:1647-1659 80. Nakas C, Yiannoutsos CT, Bosch RJ, Moyssiadis C. Assessment of diagnostic markers by goodness-of-fit tests. Statistics in Medicine. 2003;22:2503-2513 81. Nakas CT, Alonzo TA, Yiannoutsos CT. Accuracy and cut-off point selection in three-class classification problems using a generalization of the youden index. Statistics in Medicine. 2010;29:2946-2955 82. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35 83. Sherazi S, Zareba W. Diastolic heart failure: Predictors of mortality. Cardiology journal. 2011;18:222-232 84. Gibelin P, Serre S, Candito M, Houcher B, Berthier F, Baudouy M. Prognostic value of homocysteinemia in patients with congestive heart failure. Clinical Chemistry and Laboratory Medicine 2006;44:813-816 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65551 | - |
dc.description.abstract | 背景:血液中的同半胱胺酸濃度上升己經被證實和心血管疾病有很大的關聯性存在。而在心衰竭的病人上面,也可以發現不只和發生率有很大的關係之外,也可以有效的預測預後。我們設計了一個世代研究,想要探討在舒張功能不全的成年上面,同半胱胺酸的濃度上升是否是預後不良的一個危險因子。
研究方法:金山社區心血管研究計畫The Chin-Shan Community Cardiovascular Cohort (CCCC) 最初就是為了測量心血管疾病的預後及趨勢所設計的。在金山地區,年齡大於35歲則會被收入到研究內。我們將病人依照血漿中同半胱胺酸濃度的高低平均分成四組。我們有Cox proportional hazards models的方法,去計算同半胱胺酸濃度最高的那組比上濃度最低的組之危險比。我們也畫出了Receiver operating characteristic (ROC) 曲線,並且計算了曲線下的面積。另外我們也對相關的危險因子做分層分析,想要去查看是否有修飾因子的存在。 研究結果:從1990年開始,我們總共收入了3602個成年居民。最後在1994年到1995年間共有2020位居民完成心臟超音波的檢查。在這13年間,總共有75位成年死亡。在效正了許多危險因子之後,高同半胱胺酸血症(hyperhomocysteinemia)仍然和不良的預後有著明顯的關聯性存在(危險比1.07, 95%信頼區間1.01-1.14。在同半胱胺酸濃度最高的那一組的受試者有比濃度最低那組的受試者,有1.90倍的總死亡風險。而當我們使用11.11μmol/L做切點將受試族群分成兩組之後,同半胱胺酸高於11.11μmol/L的那組其總死亡風險增加0.88倍,95%信頼區間為1.07-3.29。同半胱胺酸的確是心血管疾病的危險因子,且在效正過各項因子後,仍和不良預後有著明顯的關聯性存在。 結論:本研究發現社區舒張功能不全成年中,其血漿中同半胱胺酸濃度和不良預後有著顯著的相關性存在。而在老年族群中,同半胱胺酸濃度的上升對不良預後有更好的預測能力。 | zh_TW |
dc.description.abstract | Background:Hypermohocysteinemia was found highly associated with systolic heart failure and it could also predict progosis. We conducted a cohort study to find whether hyperhomocysteinemia was associated with poor prognosis in diastolic dysfunction patients.
Method:The Chin-Shan Community Cardiovascular Cohort (CCCC) study was designated to measure the trends of cardiovascular morbidity and mortality in a community. Individuals who were aged 35 and above were enrolled. Participants were classified by quartiles of homocysteine concentration. We used multivariate Cox proportional hazards models to calculate the hazard ratio of the fourth quartiles versus the first quartile. Receiver operating characteristic (ROC) curve was constructed, and area under curve was calculated. We also performed stratification to find the effect modifier. Results:A total of 3602 participants were enrolled, and 2020 participants completed echocardiography. Among the 2020 participants, 231 individual had diastolic dysfunction. Total 75 participants died during follow-up period. After adjusted with multiple variants, hyperhomocysteinemia was significantly associated with poor prognosis with a hazard ratio of 1.07(1.01-1.14). Participants in the highest quartile had a 1.90 ( 95% CI, 0.88-4.12, p for trend, 0.026) fold risk for all cause death compared with those in the lowest quartiles. The hazard ratio was 1.88(95% CI, 1.07-3.29) using 11.11μmol/L as cutpoint. Conclusion:Hyperhomocysteinemia was significantly associated with poor prognosis in diastolic dysfunction participants. Homocysteine was a good predictor for all-cause death among old age adults. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T23:49:58Z (GMT). No. of bitstreams: 1 ntu-101-R99849032-1.pdf: 2055810 bytes, checksum: c035b1f6483e7d0901a2fa18a30e7634 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii 英文摘要 v 目錄 vii 圖目錄 x 表目錄 xi 第一章 研究背景 1 第一節 心衰竭的重要性 1 第二節 舒張性心衰竭與舒張功能不全 1 第三節 同半胱胺酸扮演的角色 3 第一項 歷史演進 3 第二項 前瞻性研究及臨床試驗4 第三項 統合分析6 第四節 同半胱胺酸和心衰竭7 第一項 生物學的觀點7 第二項 動物研究8 第三項 臨床研究8 第四項 文獻回顧 世代研究10 第五項 橫斷研究 同半胱胺酸和心臟生理的關聯性12 第六項 橫斷研究 同半胱胺酸和心衰竭之關聯性14 第二章 研究目的與假說17 第一節 研究目的17 第二節 研究假說 17 第三章 研究方法18 第一節 研究架構18 第二節 實驗的設計和研究對象的選取18 第三節 研究資料內容及收集方式18 第一項 金山社區心血管研究計畫資料收集方式18 第二項 家戶訪談及基準資料的搜集方式19 第三項 1994-1995年的追蹤方式 20 第四項 超音波的測量20 第五項 同半胱胺酸的測量21 第六項 試驗指標和定義22 第四節 統計方法22 第四章 研究結果24 第一節 研究對象基本資料及總死亡風險的分析24 第二節 同半胱胺酸的危臉比分析25 第三節 檢定修飾因子26 第四節ROC曲線及切點的計算27 第五章 討論28 第一節 整體結果概述28 第二節 研究結果與過去文獻之比較29 第三節 研究優點及限制32 第四節 未來方向及應用34 第五節 結論34 參考文獻59 附錄一 金山社區心血管研究計畫問卷70 | |
dc.language.iso | zh-TW | |
dc.title | 使用血漿同半胱胺酸濃度預測社區舒張功能不全成年之總死亡風險-13年追蹤研究 | zh_TW |
dc.title | Use of plasma homocysteine concentration to predict the risk of all-cause death in adults with diastolic dysfunction in a community – A 13-year follow-up study | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李源德(Yuan-Teh Lee),賴美淑(Mei-Shu Lai),陳文鍾(Wen-Jone chen),程蘊菁(Yen-Ching Chen) | |
dc.subject.keyword | 舒張功能不全,同半胱胺酸,總死亡風險,金山地區心血管研究計畫, | zh_TW |
dc.subject.keyword | diastolic dysfunction,homocysteine,mortality,The Chin-Shan Community Cardiovascular Cohort, | en |
dc.relation.page | 79 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-07-23 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 2.01 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。